Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 02, 2015 12:46 AM ET

Healthcare Providers and Services

Company Overview of 21st Century Oncology Holdings, Inc.

Company Overview

21st Century Oncology Holdings, Inc., together with its subsidiaries, operates as a physician-led provider of integrated cancer care services. Its radiation treatment services include external beam therapies, such as conformal radiation therapy, intensity modulated radiation therapy, and stereotactic radiosurgery, as well as internal radiation therapies, such as high-dose and low-dose rate brachytherapies. The company’s radiation treatment services also comprise image guided radiation therapy, Gamma function testing, and respiratory gating. In addition, it offers support services in the areas of psychological and nutritional counseling, as well as transportation assistance. Further, the comp...

2270 Colonial Boulevard

Fort Myers, FL 33907

United States

Founded in 1983

4,630 Employees

Phone:

239-931-7275

Key Executives for 21st Century Oncology Holdings, Inc.

Co-Founder, Chief Executive Officer, President, Executive Director, Member of Executive Committee, Member of Capital Allocation Committee, President of Radiation Therapy Services Inc. and Chief Executive Officer of Radiation Therapy Services Inc
Age: 61
Principal Financial Officers, Chief Accounting Officer, Senior Vice President, Corporate Controller and Assistant Treasurer
Age: 45
Chief Executive Officer of Medical Developers Cooperatief U A B V, Chief Executive Officer of Vidt Centro Medico, President of Medical Developers Cooperatief U A B V and President of Vidt Centro Medico
Age: 55
Chief Medical Officer
Age: 45
Chief Compliance Officer and Senior Vice President
Age: 62
Compensation as of Fiscal Year 2014.

21st Century Oncology Holdings, Inc. Key Developments

21st Century Oncology Holdings, Inc. Reports Unaudited Consolidated Earnings and Operating Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides International Revenue Guidance for the Year 2015

21st Century Oncology Holdings, Inc. reported unaudited consolidated earnings and operating results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenues of $269,509,000 against $203,390,000 a year ago. Loss before income taxes was $21,782,000 against $39,605,000 a year ago. Loss attributable to the shareholder was $24,168,000 against $14,925,000 a year ago. For the quarter, on Pro forma basis, the company reported total pro-forma revenues of $269,509,000 against $209,210,000 a year ago. Pro-forma Adjusted EBITDA was $37,209,000 against $27,236,000 a year ago. Total pro-forma revenues for the fourth quarter of 2014 were driven by the company's acquisition activity and organic growth. The increase in pro forma adjusted EBITDA was primarily due to integration of OnCure and the addition of SFRO's operations, as well as ongoing efforts on expense management. For the year, the company reported total revenues of $1,026,422,000 against $736,516,000 a year ago. Loss before income taxes was $338,061,000 against $98,680,000 a year ago. Loss attributable to the shareholder was $349,250,000 against $80,214,000 a year ago. Net cash used in operating activities was $15,368,000 against $11,577,000 a year ago. Purchase of property and equipment was $56,563,000 against $40,744,000 a year ago. Acquisition of medical practices was $50,245,000 against $68,659,000 a year ago. Reduced debt by $200 million with proceeds from Canada Pension Plan Investment Board investment. For the year, on Pro forma basis, the company reported total pro-forma revenues of $1,035,241,000 against $845,283,000 a year ago. Pro-forma Adjusted EBITDA was $150,918,000 against $118,591,000 a year ago. The increase in revenue was principally due to increased domestic census, acquisitions, stronger results from joint ventures, and international revenue growth. The net loss for the full year 2014 included impairment charges of $229.5 million, attributable to revisions of the Company's financial forecasts largely as a result of reductions in reimbursement and limited capital resources during the second quarter of 2014 that resulted in a write down of goodwill, trade name and an investment in a joint venture to their implied fair values. Pro forma revenues include $8.8 million in revenue contribution from acquisitions as if the acquisitions had closed on January 1, 2014. The fourth quarter and full year 2014 increase was due to increased domestic census, acquisitions, stronger results from joint ventures and international revenue growth. For the quarter, the company reported domestic same store treatments per day increased 2.3% in the fourth quarter of 2014 while same store freestanding revenues increased 2.0%. The growth was primarily driven by the continued expansion of physician network and strong growth in key markets. Domestic same store therapy revenue per treatment decreased 0.3% in the fourth quarter of 2014, primarily due to an increased shift in payor mix to Medicare replacement products. Total Relative Value Units per day increased by 22.4% in the fourth quarter versus the same period of the prior year due to acquisitions, same store treatment growth and service mix. On a same store basis, RVUs increased 0.2% versus the same period last year. For the year, the company reported domestic same store treatments per day increased 2.6% for the full year 2014. This was driven by expansion of ICC model as well as physician and center-level marketing efforts resulting in an increased patient census. Domestic same store therapy revenue per treatment increased 2.5% compared to 2013. For the year 2015, the company expects international revenues to surpass $100 million.

21st Century Oncology Holdings Mulls Acquisitions

21st Century Oncology Holdings, Inc. is seeking acquisitions. Daniel Dosoretz, founder and Chief Executive Officer of 21st Century Oncology Holdings said in fourth quarter and full year 2014 financial results, “We entered 2015 with the same focus on executing our strategy of organic growth combined with prudently taking advantage of attractive strategic de-leveraging acquisitions and joint ventures in order to continue delivering integrated cancer care at academic quality and create compelling value for our steadily expanding patient population."

21st Century Oncology Holdings, Inc. to Report Q4, 2014 Results on Mar 18, 2015

21st Century Oncology Holdings, Inc. announced that they will report Q4, 2014 results at 5:00 PM, Eastern Standard Time on Mar 18, 2015

Similar Private Companies By Industry

Company Name Region
Radiology Associates of Hollywood, P.A. United States
WellCare of South Carolina, Inc. United States
University Health Services, Inc. United States
East Houston Surgery Center, Ltd. United States
TheraTrust Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
September 26, 2014
--
Merger/Acquisition
May 15, 2014
Roger Williams Radiation Therapy, Llc
Merger/Acquisition
May 15, 2014
Southern New England Regional Cancer Center, LLC
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact 21st Century Oncology Holdings, Inc., please visit www.rtsx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.